In tumor types with a low frequency of NTRK fusions, recent NTRK testing recommendations suggesting using pan-Trk immunohistochemistry as a screening tool to identify cases for definitive NTRK fusion detection by NGS assay. The gene discussed is TPM3; the disease is neoplasm.